Universitäres Centrum für Tumorerkrankungen Mainz (UCT Mainz)
Klinisch orientierter Schwerpunkt / Johannes Gutenberg-Universität Mainz
Wiesmann, Nadine; Kluenker, Martin; Demut, Philipp et al.
Zinc overload mediated by zinc oxide nanoparticles as innovative anti-tumor agentJOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY. Bd. 51. 2019 S. 226-234
Verhoeven, Carole; Schmidt, Marcus; Hoenig, Arnd et al.
(E)stetrol for treatment of advanced ER+ breast cancerCANCER RESEARCH. Bd. 78. H. 4. 2018
Czauderna, C.; Koch, S.; Pilz, L. et al.
A high alpha-fetoprotein slope prior to therapy correlates with poor prognosis of patients with hepatocellular carcinomasJOURNAL OF HEPATOLOGY. Bd. 68. 2018 S. S442-S442
Surowy, Harald; Varga, Dominic; Burwinkel, Barbara et al.
A low-frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (< 60 years) and is associated with reduced DNA repair capacityINTERNATIONAL JOURNAL OF CANCER. Bd. 142. H. 4. 2018 S. 757-768
Kebenko, Maxim; Goebeler, Marie-Elisabeth; Wolf, Martin et al.
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE (R)) antibody construct, in patients with refractory solid tumorsONCOIMMUNOLOGY. Bd. 7. H. 8. 2018
Zaini, Mohamad A.; Mueller, Christine; de Jong, Tristan V. et al.
A p300 and SIRT1 Regulated Acetylation Switch of C/EBP alpha Controls Mitochondrial FunctionCELL REPORTS. Bd. 22. H. 2. 2018 S. 497-511
Schmidt, Marcus; Decker, Thomas; Fehm, Tanja et al.
A phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR plus ) / human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy - VinoMetroCANCER RESEARCH. Bd. 78. H. 4. 2018
Coombes, R. C.; Tovey, Holly; Kilburn, Lucy et al.
A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn celecoxib trial)CANCER RESEARCH. Bd. 78. H. 4. 2018
Neitzel, C.; Stroh, S.; Nagel, G. et al.
A promising building block in the chemotherapy of colorectal cancer: The first-in-class mitochondrial disruptor CPI-613NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY. Bd. 391. 2018 S. S58-S58
Mueller, V.; Park-Simon, T. -W.; Huober, J. et al.
A randomized, double-blinded pivotal study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2-pos. unresectable locally advanced or metastatic breast cancer: HER2CLIMBONCOLOGY RESEARCH AND TREATMENT. Bd. 41. 2018 S. 28-28